Past Conference Report
Thanks for participating in Pharmaceutics 2018
The 17th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems was held on October 04-06, 2018 in Moscow, Russia with the presence of professional researchers, business delegates, scientists involved in the development of high-quality education & research in all aspects. Please check the website: Pharmaceutics 2018 Conference Photographs
Pharmaceutics 2018 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various topics related to the fields of Pharmaceutics and Drug Delivery Systems. The highly exalted conference hosted by EuroSciCon was marked with the attendance of renowned and brilliant researchers, business delegates and talented student communities representing more than 30 countries around the world. The conference has tried grounding every aspect related to Pharma Industry, covering all the possible research areas.
The conference aimed a parallel rail with theme “Challenges Innovations and Advances in Novel Drug Delivery Systems”. The meeting engrossed a vicinity of cognizant discussions on Targeted Drug Delivery System: Advances and Approaches, Nanotechnology in Drug Delivery, Drug Discovery and Development Obstacles, Drug Delivery through BBB, Innovative Drug Delivery Technologies, Pharmacokinetic and Pharmacodynamic Studies, Smart Materials for Drug Delivery , Protein, Peptide and Gene Drug Delivery, Recent Advances in Drug Delivery Systems, Drug Delivery Vehicles , Nanoparticles: Innovations and Trends. The three days event implanted a firm relation of upcoming strategies in the field of Pharma Industry with the scientific community. The conceptual and applicable knowledge shared, will also foster organizational collaborations to nurture scientific accelerations.
We are thankful to all our speakers for encouraging and supporting us to conduct the conference and catapulting the same to pinnacle of success.
We would like to thank our Organizing Committee Members Dr. Vladimir P Torchilin, Northeastern University, USA , Dr. Sergey Suchkov, Sechenov University, Russia for their support throughout the conference without your cooperation which lead us to the grand success of Pharmaceutics 2018 Conference
The Organizing Committee would like to thank the moderator: Dr. Ayse Nur Oktay, Gazi University, Turkey and Olga Mikhailovna Mulina, N D Zelinsky Institute of Organic Chemistry-RAS, Russia for their valuable contribution which resulted in smooth functioning of the conference.
We would also like to thank our Poster judge Dr. Sergey Suchkov, Sechenov University, Russia for the evaluation of Poster Presentations.
The meeting was embarked with an opening ceremony followed by Keynote Sessions and followed by series of lectures delivered by Honorable Guests and members of the Keynote forum. The highlights of the meeting were the eponymous lectures, delivered by:
Vladimir P Torchilin, Northeastern University, USA
Alexander O Terentev, N D Zelinsky Institute of Organic Chemistry-RAS, Russia
Muna Abubaker, University of Salford, UK
Essam Ghanem, Celyad Biopharmaceutical, Belgium
Dushkin Alexandr Valerevich, Institute of Solid State Chemistry SB RAS, Russia
Alyabyeva Zhanna Yurievna, Pirogov Russian National Research Medical University, Russia
Olga V Dementeva, Frumkin Institute of Physical Chemistry and Electrochemistry of RAS, Russia
Ruey-an Doong, National Chiao Tung University, Taiwan
Jayvadan K Patel, Sankalchand Patel University, India
Tamara Zwain, University of Central Lancashire, UK
Yong-Xi Li, Medpace Bioanalytical Laboratories, USA
Sergey Suchkov, Sechenov University, Russia
Dimosthenis Mavrilas, University of Patras, Greece
Ayse Nur Oktay, Gazi University, Turkey
Ilya Yakavets, Belarusian State University, Belarus
Ruth Belostotsky, Shaare Zedek Medical Center, Israel
Suneel I Majagi, Gadag Institute of Medical Sciences, India
Zahid Iqbal, Isra University, Pakistan
Fatemeh Farjadian, Shiraz University of Medical Sciences, Iran
Anika Staack, MEDICE, Germany
Poster competition also held for the young scientists and the best poster presenter has been awarded by the Dr. Sergey Suchkov, Sechenov University, Russia.
Pharmaceutics 2018 had an effective networking session which enables the professionals and scientists to get involved & enlightened them in all perspectives. We also like to thank all the delegate professionals from various countries like India, Nepal who attended the conference shared their industrials experiences in networking sessions. Please check the website: Pharmaceutics 2018 Conference Photographs to visualize the conference photographs
EuroSciCon is prerogative to thank the Organizing Committee Members, Keynote speakers and Chairs on transcribing the plenary sessions in a diversified and variegate manner to make this conference an enviable artifact.
Pharmaceutics 2018 would not have reached the pinnacle if not with the support of International, multi-professional steering committee and coordination of International Journal of Drug Development and Research, American Journal of Drug Delivery and Therapeutics and Journal of Pharmacy and Pharmaceutical Research.
With the grand success Pharmaceutics 2018, we are glad to announce our next upcoming conference “18th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems ” which is going to be held in Warsaw, Poland during October 14-15, 2019 on the theme "Exploring the future of Pharma Industry through Pharma research, Nanomedicine and Drug Delivery Systems"
Bookmark your dates…
Hoping to meet you again coming year at Warsaw!!!
EuroSciCon invites participants from all over the world to attend ''18th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems” during October 14-15,2019 at Warsaw, Poland which includes prompt keynote presentations, Oral talks (Speaker Forum and Young Research Forum), Poster presentations, Symposium, Workshops and Exhibitions.
Pharmaceutics 2019 spreads an extensive range of critically important sessions from basic research to recent innovations. The theme: “Exploring the future of Pharma Industry through Pharma research, Nanomedicine and Drug Delivery Systems” is designed for professionals at all levels and career phases of the Pharma industry, who want to improve their understanding of what will drive and shape the future of the market.
Pharmaceutics 2019 offers a best stage with its proficient legitimate program to the social event of individuals which consolidates instinctive board discoursed, keynote addresses, all-hands gatherings and notice sessions on the topics Clinical Trails, Drug Discovery, Nanotechnology, current issues in Bioequivalence, Pharmaceutical Innovation in the 21st Century, Nanomedicine, Drug transport, Gene Therapy, Therapeutic Biological Products, Pharmaceutical Packaging, BABE, Biosimilars, Drug Delivery Technologies, Drug delivery advances and challenges, Pharmacovigilance, Tissue Engineering, Regenerative Medicine, Pharmaceutical Chemistry, Pharmaceutical Analysis, new coherent approaches to managing overall managerial measures, Pharmacotherapy, Generic Drugs, Biopharmaceutical Companies and Market Analysis, The get-together invites delegates from over the globe giving a predominant stage, interconnecting the latest research, creative enhancements in the field and furthermore helpful viewpoints. This conference also provides a podium to exhibit the brand-new equipment relate to Pharma Industry for the industries and companies in which they can be benefited in the global market moreover they can upgrade their product value.
Poland is an attractive market for the pharma industry. This is bolstered by the fact that Poland is a member of the European Union, providing it with stability and a predictable regulatory environment. Poland is the largest pharma market in Central and Eastern Europe and the sixth largest in Europe. Poland’s stability and bright outlook attract most global pharmaceutical companies. Many pharmaceutical companies have their Central and Eastern European headquarters in Poland. The Polish pharmaceutical market has an exceptionally high share of generics drugs. The share of generics in the total pharma market (pharmacy and hospital), taking into account manufacturer prices, was about 70%.While the Polish pharmaceutical market has largely consisted of high-volume generics, a number of Polish companies have started R&D operations focused on novel molecules, innovative therapies, and biosimilar products.
Clinical research studies started about 25 years ago, in the 1990s, in Poland, making it a mature and well-established market with a long history of studies conducted. Polish clinical sites began to participate in international collaborative efforts through local pharma companies. Poland is the largest clinical trials market in CEE (Central and Eastern Europe)/CIS (Commonwealth of Independent States) and accounts for roughly 20% of clinical trials in Eastern Europe. More than 400 studies are registered in Poland every year. According to the Association for Good Clinical Practice in Poland, about 40,000 patients participate in clinical trials each year. Poland’s regulatory processes are predictable and transparent.
Nobel laureates in Health Care and Medicine
Supply Chain companies
Pharmaceutical Industrial Giants
Research Institutes and members
Regulatory Operations and Affairs Outsourcing experts
Toxicology and Pharmacology Students
Pharmacy Societies and the people Associated
Why to attend our Conference:
This event will provide an opportunity to build and expand your network with various people and gives chance to make collaboration with other universities and research labs. It also helps you to meet the experts in the relevant field of study. It gives the access to novel instruments in the market. This conference plays a major role in your business development and maximizes the profit.
- Speaker Presentations
- Poster Display
- Symposium hosting
- Workshop organizing
- Association Partnering
- Collaboration proposals
- Academic Partnering
- Group Participation
- Poster Competition (Winner will get Best Poster Award)
- Young Researcher Forum (YRF Award to the best presenter)
- Student Attendee
- Group registrations
- Speaker Presentations
- Symposium hosting
- Book Launch event
- Networking opportunities
- Audience participation
- Exhibitor and Vendor booths
- Sponsorships opportunities
- Product launch
- Workshop organizing
- Scientific Partnering
- Marketing and Networking with clients
Track 1: Nanotechnology in Drug Delivery
Nanotechnology became the driving force behind various evolutionary changes in the scientific field. Nanotechnology based drug delivery enhanced the efficacy of available medicaments and enabled to create entirely new medical products. Nanotechnology has opened the door to new innventions to stimulate the reconstruction of complex tissue structures. Nanoparticles are used to deliver the drug to the specific diseased cell where particles attract to the diseased cell and provide treatment. By this technique, we can minimize the damage of healthy cells in the body.
Nanotechnology-dependent detectors e.g. nanowires, nanotubes, nanoparticles, cantilevers, and nano arrays consume low sample and enhance fast detection of disease. Target based Nano probes (e.g. magnetic nanoparticles, quantum dots, and carbon nanotubes) provide a faster, less invasive and more accurate way for diagnose of diseases. Reporting in vivo efficacy of therapeutics and helping surgeons to locate tumors are other opportunities of nanotechnology.
Some nanotechnology-based drugs that are commercially available are- Abraxane, approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer. Doxil was approved by the FDA for the treatment of ovarian cancer.
The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.
Targeted drug delivery is a kind of drug delivery, a method of delivering medication to a patient in a manner that increases the concentration only in particular area of the body. The goal of a targeted drug delivery system is to prolong, localize and have a safe drug interaction with the diseased tissue. The advantages of the this drug delivery are 1. reduction in the frequency of the dosages taken by the patient 2. have an uniform effect of the drug, 3.reduction of drug side-effects 4. reduce fluctuation in circulating drug levels 5.maintain the optimum plasma and tissue drug levels in the body. A small portion of the medication reaches the affected organ in Chemotherapy and roughly 99% of the administered drug does not reach the tumor site.
The following criteria must be taken into consideration while designing a targeted drug delivery: the drug property,the route of drug delivery, the targeted site, disease and the side effects of drug. There are two kinds- active targeted drug delivery such as antibody medications and passive targeted drug delivery such as the enhanced permeability and retention effect.
Drug delivery is the action of administering a medication into the body for a therapeutic effect through various routes. Drug delivery technology modifies drug release profiles, pharmacokinetic parameters to improve product efficacy as well as patient convenience. Conventional routes cannot deliver compounds such as proteins, antibodies, vaccine and gene based drugs because these routes are susceptible to enzymatic degradation or cannot be absorbed into the systemic circulation efficiently due to large molecular size and charge issues.
Technologies include controlled needle-free devices, sustained, controlled transdermal delivery technology and penetration matrix technology for non-invasive delivery. Many innovative technologies for effective drug delivery have been developed that includes implants, nanotechnology, cell and peptide encapsulation, micro fabrication, chemical modification.
Biotechnology advances are leading to develop medications to target diseases more effectively and precisely.
Nanotechnology delivers drugs to targeted cells by nanoparticles. The overall drug consumption and side-effects are lowered significantly by depositing the active drug in the particular site and preventing administration of booster doses. Nanotechnology based devices are less invasive. They can be safely implanted inside the body as biochemical reaction times are much shorter.
The goal of drug delivery systems is to deliver medications to specific target parts of the body through a medium that can control the therapy’s administration. To achieve this goal, researchers are switching to advances in the worlds of micro- and nanotechnology.
The recent advances in the peptide,protein drug delivery systems are PEGylation and Depo-foam technology. Cell-penetrating peptides (CPPs) act as cargo carriers and constitute current medical research. CPPs to transport hydrophilic macromolecules into cells, thus, assist to execute biological functions. CPPs do not destroy the integrity of the cell membranes so they are considered more efficient and provide new avenues for research and applications in life sciences.
Needle-free drug delivery systems are novel ways to introduce various medicines to patients. PowderJect Pharmaceuticals one of the first companies to develop a needle-free technology for injecting powdered drugs into the skin. Needle free devices can take the form of power sprays, edible products, inhalers, and skin patches
Transdermal patches are user-friendly, convenient, painless and offer improved patient compliance.
Nano drug delivery systems such dendrimers, fullerence, nano pores, nanotubes, nano shells, quantum dots, , nanovaccines, revolutionized drug delivery systems. Thus nanomaterial can be used for strategic development of new drug delivery systems and reformulate existing.
Nanoparticles are generally less than 100 nm in dimension and consist of different biodegradable materials such as natural or synthetic polymers, lipids, or metals. Nanoparticles are taken up by cells more efficiently than larger micromolecules. Nanoparticles have high surface area to volume ratio thus allowing many functional groups for attachement. The small size of nanoparticles allows them to accumulate at sites.
Nano particles can (1) enhance the efficacy and minimize adverse reactions associated with drugs; (2) enable new classes innovations; and (3) encourage the re-investigation of pharmaceutically suboptimal but biologically active new molecules that were previously considered undevelopable.
Nanoparticles are used in drug delivery to improve the uptake of poorly soluble drugs.
As per BCC Research the global market for nanoparticles in the life science forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate (CAGR) of 22%.
Track 6: Drug Delivery: Facing Challenges
Innovative, non-invasive delivery includes improvement of patient acceptability and compliance, improvement in public safety, decrease of administration costs and a reduction of adverse effects. Enzyme degradation, acid degradation, hydrolysis and low permeability of intestinal epithelium in the GI tract surfaces make oral administration a non-viable delivery method. Proteins are administered parenterally as oral administration cause low bioavailability in the GI tract. It has become a challenge to achieve consistent and adequate bioavailability levels for oral administration.
Economic and financial barriers also stand in the way of implementing nano medicine. The limited availability of reimbursement by public and private health insurers for expensive new diagnostic tests has emerged as a major impediment to the deployment of personalized medicine. Nanoproducts encounter even greater hurdles because of their costs and complexity, cytotoxicity of nanoparticles are main concern of future research.
Advances in medical science, research and development (R&D) are changing the dynamics of the life science industry which includes pharmaceuticals and healthcare. The development of new drugs enhances the development of different drug delivery systems, which is further driven by innovation in technology, R&D and scientific advancements. Advances in understanding human diseases and medical treatments are opening new opportunities in the pharma industry. A better technology for drug administration or delivery is in demand now.
Track 7: Drug delivery through BBB
One of the biggest challenges in the drug discovery and development for CNS disorders is to achieve significant blood–brain barrier (BBB) penetration.
Many drugs do not have high lipid solubility, low molecular size and positive charge to traverse BBB. The issues associated with the blood–brain barrier are 1. The drug produced allows only a small portion to pass through the barrier 2. Binding to other proteins in the body makes the drug ineffective or pass through the barrier with that adhered protein. 3. The presence of enzymes in the brain that could render the drug inactive. All of these problems must be addressed to deliver effective drugs to the brain.
Developed strategies enhance the capacity of drug to cross the BBB by modifying the drug or by coupling it to a vector for receptor-mediated or adsorption-mediated transcytosis.
Compounds using BBB technology in the clinical development would reach approximately eight by 2019. The global market for BBB technologies was valued at $38.7 million in 2014. The market is expected to grow to $471.5 million by 2019, and register a tremendous 64.9% CAGR from 2014 through 2019.
Track 8: Novel Drug Delivery Systems
It is defined as the method by which a drug is delivered can have a significant effect on its efficacy i.e. the drug become more efficient in order to minimize drug degradation, adverse effects and to increase the bioavailability to produce betterresult. NDDS covers various aspects like pharmacokinetics & pharmacodynamics, non-specific toxicity, immunogenicity, bio recognition, and drug’s efficacy based on preferable approaches that include polymer science, pharmaceutical technology, dispensing pharmacy, packaging technology, bio conjugate chemistry, and molecular biology.
Track 9: Drug delivery vehicles
A drug carrier enhances the selectivity, effectiveness and safety of drug administration. Drug carriers are mainly used to control the release of a drug into systemic circulation. This can be accomplished either by slow release of the drug over a long period of time (typically diffusion) or by triggering the release at the target by stimulus, which include pH changes, application of heat and activation by light. Drug carriers improve the bioavailability of poorly water soluble drugs or membrane permeable drugs.
An ideal drug delivery vehicle must be non-toxic, non-immunogenic, biocompatible and biodegradable Different methods of drug attachment to the carriers include adsorption, integration, encapsulation, and covalent bonding.
Track 10: Protein, Peptide and Gene Drug Delivery
Peptides and proteins have more potential as drug delivery systems. Compared with the small size drugs, peptides and proteins can be highly selective as they have multiple contact points with their target. Increased selectivity results in decreased side effects and toxicity. Peptides can be designed to target a broad range of molecules and provide opportunities in oncology, infectious disease and endocrinology fields. The market for peptide and protein drugs is estimated to be greater than US$40 billion/year, or 10% of the pharmaceutical market .At present there are over 100 approved peptide-based drugs in the market. The pharmaceutical scientists have approaches to develop the protein and peptide delivery formulations by noninvasive routes.
Gene therapy is defined as incorporation of genetic material i.e, DNA or RNA, in the cellular gene regulation system, either to correct the expression of a malfunctioning gene or to modulate the cellular functions. Nanotechnology advances gave rise to the development of nanoparticle-DNA delivery systems. Gene delivery is an important part of genome evolution. Gene delivery utilizes non-immunogenic vectors capable of cell specificity that can deliver an adequate amount of transgene expression to cause the desired effect. Gene therapy advanceshave enabled a variety of new methods and gene targets to be identified for possible applications. Gene delivery has been utilized to generate a hybrid biosynthetic vector to deliver a possible vaccine.
Pharmacokinetics describes how the medicament gets influenced after administration, followed by absorption, distribution, metabolism mechanisms and excretion of the drug substance. Pharmacokinetic knowledge assists prescribers to adjust dosage accurately and precisely. Clinical kinetics is defined as the applications of pharmacokinetic principles in the safe and adequate management of individual patient. Toxic pharmacokinetics is defined as the applications of pharmacokinetic principles to the designation, behaviour and interpretation of drug safety evaluation studies.
Pharmacodynamics describes biochemical, physiological, and molecular effects of drugs on the body and involves receptor binding (including receptor sensitivity), post receptor effects, and chemical reactions. The pharmacological response depends on the drug binding to its target. The effect of drug presence at the site of action is measured by drug-receptor binding.
Drug discovery is the process in which potential new medicines are recognized and comprises an effective range of scientific disciplines, including biology, chemistry and pharmacology. The integration of pharmacodynamics and pharmacokinetic parameters in non-clinical pharmacology studies plays a key role in drug discovery for efficacy and safety assessment, in particular for translation from the non-clinical to clinical field and process of drug discovery include the identification , synthesis, characterization, screening, and assays for therapeutic efficiency and modern drug discovery involves the identification of screening areas, medicinal chemistry and optimization of those areas to increase the affinity, selectivity, efficacy/potency, metabolic stability, and oral bioavailability.
FDA provides scientific and regulatory advice to bring new therapies to market. In 2018, FDA has approved 43 new drugs which are currently in the market. Every year, CDER approves series of new drugs and biological products. The availability of new drugs represents new treatment options for patients and advances in health care. Some of these are often innovative new products that never before have been used in clinical practice. A new chemical entity (NCE) is a drug that contains no active molecule that has been approved by the FDA in any other application submitted under the Federal Food, Drug, and Cosmetic Act
Pharmacovigilance and Risk Management comprises set of pharmacovigilance activities designed to identify, characterise, prevent or minimize risks related to medicinal products which includes the assessment of the effectiveness of their clinical interventions and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to review softwares used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO’s, pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates. Pharmacovigilance legislation focus on the rules and laws to follow in Pharmacovigilance practice. The Role of Pharma industries in the improvement of pharmacovigilance systems plays a crucial role to maintain the safety data, Detection and Evaluation of drug safety signals through medical devices reporting. Pharmacovigilance scope also deals as Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines
Prescription Safety is the pharmacological science ensuring security and related to the aggregation, area, assessment, watching, and repugnance of hostile side effects with pharmacological movement of pharmaceutical things. As per US FDA a drug is seen as protected by its look, collecting technique and delayed consequences of animal testing and clinical tests. In this conference, we look at Drug security and its applications in various fields, for instance, Software, Training.
Track 14: Smart Materials for Drug Delivery
Materials are called “smart” when these materials have the ability to respond to stimuli and have high potential in delivery systems. The drug delivery to specific parts in the human body using smart materials has been approaching the forefront place in research for the past few decades. Materials for delivering drugs that do not interact non-specifically within the body must design drug carriers
Polymers have played an important role in the advancement of drug delivery technology by providing controlled release of agents in constant doses over longer duration and release of both hydrophobic and hydrophilic drugs. The greatest advantage of polymers is their ability to chemical modification, resulting in defined chemical composition, surface functionality and the potential for three-dimensional structures. Several polymers widely used are synthetic polymers and natural polymers.
Nano materials are used in controlled drug delivery. Drug-delivery systems can be designed with controlled composition, shape, size and morphology. Nanoparticles surface properties can be manipulated to increase solubility, immunocompatibility and cellular uptake.
Natural gums are widely used in the drug delivery system because of their wide availability, inexpensiveness.
Track 15: Herbal Novel Drug Delivery
Novel drug delivery systems address the drawbacks of the traditional drug delivery systems. We have a knowledge of Ayurveda. So it is important to integrate novel drug delivery system and Indian Ayurvedic medicines to combat serious diseases.
Reasons for using herbal medicines are 1. Growing concern over the reliance and safety of drugs 2.Failure of modern medicine to treat most common health conditions 3. Natural medicines are producing better results without adverse effects.
Novel herbal formulations like polymeric herbal Nano-carriers, phytosomes, herbosomes, pro-niosomes, Nano emulsions, microsphere, transferosomes, implants and ethosomes has been reported using bioactive plant extracts. Advantages include Solubility, bioavailability enhancements, reduced toxicity, improved pharmacological activity, sustained delivery, and protection from physical and chemical degradation. Many formulations are produced from herbal drugs such as curcumin, quercetin, silybin, bilobalide, marsupsin, andrographolide.
According to WHO due to poverty and lack of access to modern medicine as well as self-belief, about 65-80% of the world's population living in developing and developed countries depends on plants for primary health care facilities.
Track 16: Preformulation and Formulation Aspects
Preformulation studies are important for various phases of clinical trials. Preformulation studies act as the first step as well as the scientific foundation for formulation design and development. These studies provide guidance in selection of drug, excipients, to determine chemical composition, physical pattern and assist in adjustment of pharmacokinetic profiles. Improving public safety measures and intensifying product quality, safety, accuracy are the other characteristics.
The main purpose of pre-formulation studies is to improve compatibility with the other ingredients and develop stable, potent and safe dosage form. Physico-chemical parameters, drug solubility studies, partition coefficient, dissolution kinetics, polymorphism and stability profiles play a significant role in preformulation studies. These studies furnish the information regarding the degradation process, toxic effects and adverse conditions. So Preformulation is an interdisciplinary basis in drug development.
Formulation is defined as the process in which different chemical substances including the active ingredient are compounded to produce a final dosage form. Developed formulations should be stable, safe and acceptable to the patient.
Track 17: Novel Vaccine Delivery Systems
Vaccine is a material that induces an immunologically mediated resistance to a disease. Vaccines are generally composed of killed or attenuated organisms or subunits of organisms or DNA encoding antigenic proteins of pathogens. Vaccines though exceptionally selective and specific in reacting with antibodies often fail to show reactions in circumstances such as shifts in epitopic identification center of antibody and are poorly immunogenic. These vaccines require boosting with agents called adjuvants in order to induce an effective immunity. Adjuvants potentiate the immunostimulatory property of the antigen and are non-immunogenic, nontoxic, and biodegradable in nature.
Conventional immunization regimen involves prime doses and booster doses. Immunization failed as patients neglect the booster doses. These reasons led the development of new generation of prophylactic and therapeutic vaccines to promote effective immunization. Vaccines allow for the incorporation of doses of antigens so that booster doses are no longer needed as antigens are released slowly in a controlled manner. Attempts are being made to deliver vaccines through carriers as they control the spatial and temporal movement of antigens to immune system thus leading to their sustained release and site targeting. Carrier systems such as liposomes, microspheres, nanoparticles, dendrimers, micelles and ISCOMs are being investigated and developed as vaccine delivery systems
Activities have been increased regarding the development and research on various printing techniques in formulation of dosage forms. These technologies offer flexibility in manufacturing, pave the way for personalized dosing and dosage forms.
Drug delivery from 3-dimensional (3D) structures is quick growing area of research. 3DP can design solid dosage forms with variable densities and diffusivities, complex internal geometries, multiple drugs and excipients.
3DP uses computer aided technology and programme to transform 3D computer aided designs (CAD) into life-changing products. These develop more effective and patient-friendly pharmaceutical products as well as bio-inspired medical devices. Levetiracetam (SPRITAM®) tablet a pharmaceutical product is developed by using 3DP technology.
3DP offers advantages like (a) high production rates due to its fast operating systems, (b) ability to achieve high drug-loading with desired accuracy mainly for potent drugs that are applied in small amount , (c) reduction of material wastage that can save in production cost and (d) amenability to pharmaceutical active ingredients including poorly water-soluble drugs, proteins as well as drug with narrow therapeutic windows.
3D structures can be printed on a variety of surfaces with characteristic permeability, porosity, hydrophobicity/hydrophilicity and surface energy. Scientists in collaboration with CAD designers have produced new medical devices ranging from pharmaceutical tablets to surgical transplants of the human face and skull, spinal implants, prosthetics, human organs and other biomaterials.
Track 19: Clinical Research and Clinical Trials
Clinical trial is a part of clinical research that follows particular protocol, or plan of action. Clinical trials are mainly performed to obtain data on safety and efficacy of the new developed drug, this data is mandatory for further approval of the drug and to bring it into the market. Clinical trials, especially those taking new medications, regularly begin after effective examines.
Clinical trials are classified into 4 types. The fourth trial occurs after the FDA has cleared a specific medication or treatment and keeps on following the security of the treatment. A clinical review includes inquire of utilizing human volunteers (called members) that add to therapeutic learning. Test potential medicines in human volunteers to see whether they ought to be endorsed for more extensive use in the all-inclusive community
The clinical trials market size was valued at USD 40.0 billion in 2016 and is expected to grow at a CAGR of 5.7% until 2025.
The interventional study design is the most essential method of conducting clinical trials across the globe. As per the statistics provided by the U.S. FDA, over 126,000 trials are currently being conducted by means of this method. Based on this indication, oncology is anticipated to witness the fastest growth.
Regulatory affairs is a new profession which developed from the governments desire to protect public by controlling the safety and efficacy of products in areas including pharmaceuticals , industrial pharmacy, veterinary medicines, medical devices. Regulatory Affairs is involved in the development of new medicines from early stage, by incorporating regulatory principles, by preparing and submitting the relevant regulatory documents to health authorities. Regulatory Affairs is actively involved in every step of development of a new medicine and in the post-marketing activities with authorized medicines. The Regulatory Affairs department is an essential part of the organizational structure of pharmaceutical industry. Internally it assist at the interphase of drug development, manufacturing, marketing and clinical research. Externally it is the key interface between the company and the regulatory authorities.
The biopharmaceutical sector in US enjoys 17% of all domestic R&D funded by the country and in return gave $2.5 trillion cumulative addition in economic output in 2016. Companies involved in the pharmaceutical manufacturing have grappled in recent years owing to the largest waves of drug patent expirations in history. As a consequence enabling low-price generic drugs to inundate the market. Many pharmaceutical manufacturers have contended with intensifying competition from generic manufacturers and cutting into revenue growth. Until the next five years till 2022, investments in research and development that generate a high return will occur as many pharmaceutical manufacturers strengthen their drug pipeline with orphan drugs.
Recently, engineers have shown inclination to single-use, modern and continuous manufacturing technologies to improve efficiency, safety and minimize scale-up steps and technology transfer problems in the pharmaceutical industry. Lot of these innovations are driven by updates instigated by the FDA. The changes are inevitable; especially in the already aging biopharmaceutical sector of the industry, where original processes are overly complex and are characterized by inefficiency, and occasionally, inherent unpredictability.
Track 22: Pharmaceutical Chemistry
Pharmaceutical chemistry is a branch that includes synthetic organic chemistry, pharmacology and biological specialties, where they involve in the design of drugs, synthesis and development. Pharmaceutical chemistry focuses on small molecules / organic entities encompassing synthetic organic chemistry, aspects of natural product chemistry and computational chemistry in close relation with chemical biology, enzymology and structural biology, together with the goal of discovery and drug development of new different agents. Speaking in practical terms, it involves chemical aspects of identification and, subsequently, a systematic and exhaustive synthetic alteration of new chemical entities to make them appropriate for use. It includes synthetic and computational aspects of the study of drugs and agents existing in the development in relation to their biological activities to understand their structure-activity relationship (SAR). Pharmaceutical chemistry focuses on the aspects of medicines and aims to ensure the adequacy, efficiency of the purposes of the medicines.
Track 23: Pharmaceutical Analysis
Chromatography and Mass Spectrometry are extensively used in the drug development stage of generic products. The ICH Q3B guidelines address the reporting threshold, identification threshold, and threshold for impurities in the product. Chromatography (LC) and Gas Chromatography (GC) are extensively used to analyze stable compounds. Labile compounds require derivatization prior to Liquid Chromatography or Gas Chromatography analysis. For certain analyses, Liquid Chromatography- Ultraviolet Detection (LC-UVD) and Gas Chromatography-Flame Ionization Detection (GC-FID) techniques may be deemed suitable. However, Liquid Chromatography-Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectrometry (GC-MS) are techniques of choice when higher specificity and sensitivity are required. Gas Chromatography-Electron Capture Detection (GC-ECD) techniques are commonly used for halogenated PGIs/GIs to enhance sensitivity and selectivity. Some spectroscopic techniques like Nuclear Magnetic Resonance (NMR), light scattering, and Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) are used in analyzing PGIs/GIs.
Track 24: Biologics and Biosimilars
A biopharmaceutical, otherwise called a biologic therapeutic item or biologic, is any restorative item made in, extricated from, or semi orchestrated from organic sources. Not quite the same as synthetically incorporated pharmaceuticals, they incorporate immunizations, blood segments, allergenic, substantial cells, quality treatments, tissues, recombinant protein and living cells used as a part of cell treatment. Biologics can be made of sugars, proteins, nucleic acids, complex mixtures of these substances, from live cells or tissues. They are confined from normal sources—human, creature, or microorganism. Phrasing encompassing biopharmaceuticals fluctuates amongst gatherings and elements, with various terms alluding to various subsets of therapeutics inside the general biopharmaceutical class. Some offices utilize the terms natural items or remedial organic item to allude particularly to macromolecular items like protein-and nucleic acid–based drugs, recognizing them from items like blood segments or antibodies which are extricated specifically from a natural source Gene-based and cell biologics are at the front line of biomedical research, and might be utilized to treat therapeutic conditions for which no different medications are accessible.
Track 25: Pharmaceutical Packaging and Marketing
Packaging is one of the largest industrial sector in the world that worth several billions. Pharmaceutical packaging are of 3 types, which are: solid packaging, semi-solids packaging and liquid packaging. The pharmaceutical packaging is a very profitable industry and it is estimated that for 2022 it will reach USD. 8.24 billion. Pharmaceutical packaging represents a meagre percentage of this colossal market. The Global Logistics Market is expected to grow at a CAGR of 7.0% from 2016-2021 and CAGR of 5.6% from 2021-2027. By 2020, pharma cold-chain logistics will be worth $16.7 billion, and non-cold chain at $77.1 billion. The market was estimated at $14.84bn in 2016 and is expected to grow to $28.75bn in 2027.
A nonspecific medication is characterized as "a medication item that is referred to a brand/reference medication item in measurements of quality, quality, execution attributes, and planned utilization." It is characterized as a term alluding to any medications showcased under its concoction name without any publicity as opposed to the promoted mark name under which the medication is sold out. They are not connected with a specific organization but nonspecific medications are liable to the directions of the nation’s admirations where they are apportioned. Worldwide nonspecific is marked with the name of the maker and the received name of the medication. A nonspecific medication and OTC Drugs must have indistinguishable dynamic fixings.
Generic drugs allow access to health care for all Americans. They are brand-name drugs copies and are the same as those brand name drugs in dosage form, safety, efficacy, strength, administration routes, quality, performance and intended use. Health care professionals can be assured that FDA approved generic drugs have met the same standards as the innovator drug. All generic drugs approved by FDA should have the same high quality, strength, purity and stability as brand-name drugs. The generic manufacturing, packaging, and testing methods must pass the same quality standards as those of brand name drugs.
Tissue Engineering is characterized as understanding the standards of tissues and its development by practical trade of deficient tissue for clinical utilization. Tissue building deals about the study of combination of cells, designing, materials strategies, physicochemical and biochemical components to replace or enhance natural tissues. Tissue Engineering utilize Scaffolds to form functional tissues and organs, which can be implanted back into the donor host with the use of engineering techniques and materials process along with some physicochemical factors. It is related to more than one branch which applies engineering knowledge as well as life science concepts towards the development of biological substitutes which can enhance or restore physiological characteristics of organ.
Regenerative Medicine is branch of translational research in tissue designing which manages the way towards supplanting, recovering human cells, tissues or organs to re-establish capacity. Instruments used to understand the results are tissue building, cell treatments, restorative gadgets and manufactured organs.
Transdermal Drug Delivery system is a part of drug delivery system and involves more research. Drugs having long pharmacokinetic half-lives are considered to be unfit for transdermal application. By the increased number of marketing authorization applications along with recent scientific developments for transdermal patches, the need for clear guidance and reserach on specific requirements for this dosage form increased.
The emergence of technological innovations in transdermal patches is expected to provide the market with advances growth opportunities over the coming years. Transdermal Drug Delivery system was valued at $32,516 million in 2016, and is estimated to reach $61,689 million by 2023, growing at a CAGR of 9.5%.
Track 29: Pharmaceutical Technology
Pharmaceutical technology is the scientific knowledge or technology utilized in pharmacy, pharma companies,pharmacology, toxicology and the pharmaceutical industry. It excludes design, techniques, devices and instrumentation in the manufacture, preparation, synthesis, compounding, dispensing, packaging, and accumulating of narcotic and other preparations used in diagnostic, to determine procedures and in the treatment of patients.
Pharmacotherapy can be characterized as the treatment, counteractive action of disease by methods for medications of the synthetic or organic root. It positions among essential techniques for therapeutic treatment, together with surgery, physical therapy, radiations, and psychotherapy. Although it is practically difficult to appraise the correct degree of pharmacotherapy effect on human well-being, pharmacotherapy together with enhanced sanitation, eating regimen and better lodging has improved individuals. Phenomenal advancements in genomics and atomic science offer a plenty of new medication targets. The utilization of present day manufactured strategies enhances the blend of medication in shorter circumstances than at any other time.
Track 31: Routes of Drug Administration
The route of administration is the path through which the dosage form (active substance) is administered into the body for treatment of various diseases and disorders. Routes of administration are classified based on 1.the location at which the dosage form is applied 2. Target of action. These include oral, topical and enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).
Taking them correctly and understanding the right way to administer can reduce the risks. The route used to administer a drug depends on three main factors: 1. the part of the body being treated 2.the way the drug works within the body 3.the formula of the drug. These routes enhance the bio availability of drug molecule.
The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market analysis is based on route of administration, facility of use.
Poland's pharmaceutical market is set to expand at a local currency compound annual growth rate of 8.3% between 2017 and 2022, reaching PLN64.25bn (USD19.36bn). The prescription drug market will drive growth, increasing its market share from 63.1% in 2017 to 68.2 by 2022.
Poland: Pharmaceutical Market Forecast
f = Fitch Solutions forecast. Source: AESGP, Fitch Solutions
Increased healthcare financing a boon to drug makers. The outlook for Poland's pharmaceutical market remains positive, with growth anticipated to experience an uptick in the coming years. Prescription drug market to drive market growth. We note that the market share of prescription medicines, at 63.1% of total drug sales in 2017, is relatively small relative to Poland's regional peers, on account of the large over-the-counter (OTC) medicine sector. Moreover, medicine reimbursement accounts for just shy of 30% of total medicine sales and less than half of prescription sales on account of high levels of co-payments. Indeed, between 2012 and 2017, patients paid approximately 57% of prescription medicine costs. However, these co-payments have been on the downtrend in recent years which is set to continue. As a result, access to medicines will continue to improve, driving the prescription drug market. Over the coming years, we anticipate a more significant shift towards increased prescription medicine consumption through this increase in medicine reimbursement funding.
The Polish pharmaceutical industry is set to rise from $9.4 billion in 2016 to around $11 billion by 2021, according to research and consulting firm GlobalData. Poland has one of the most developed and evolved healthcare systems in the Commonwealth of Independent States region, as the population receives mandatory universal healthcare coverage, and reimbursement is a major factor in increasing compliance and access to medicines – all factors that will spur the pharmaceuticals market. Drug prices are typically lower than in other EU member countries which enhances affordability and boosts growth in the sector. An increase in funds from the EU will boost opportunities for manufacturers and investors. The Operational Program for Infrastructure and Environment 2014-2020, financed by both the European Development Fund (ERDF) and the European Social Fund (ESF), aims to increase foreign investments in Poland. A total of €2.28 billion ($2.92 billion) has been earmarked for the implementation of measures relating to healthcare.
The pharmaceutical industry comprises of companies that are engaged in research, development, manufacture and distribution drugs for human or veterinary use. The primary function of the research-based pharmaceutical corporations is to create value by discovering and producing effective medicines, vaccines and services that improve patients’ well-being, and can be sold in markets at a profit. As well as increasing shareholder value, this contributes significantly to the quality and protection of life and helps make the world a better place. In the past 60 years, innovation and technology have driven huge improvements in global health.
The pharmaceutical industry is undergoing a tremendous deal of change. There are many pharmaceutical companies, who are providing the better products. The Pharma industry is one of the most sought after, and flourished industries. As the pharmaceutical drug manufacturers are one of the reasons for the economic well being of a nation. On the other hand, we can say that the Pharma industry is responsible for the economic development. That is the main reason for both research and development of newer and better products for various kinds of diseases.
Market Analysis of Global Pharmaceutical Industries:
The global $1.12 trillion market in 2022, will rise at a faster clip during 2016-2020, then slow down a bit as major patent expiration take hold. It is expected that the global market declined by 1.0% in 2015, but will grow by 4.8% this year. Prescription sales excluding generics will rise 4.4% this year, and expected to reach $1.006 trillion in 2022. Generics sales will increase from $73 billion in 2015 to $115 billion in 2022, and constitute 10.2% of prescription sales at that point only 0.3 percentage points more than it is now.
The global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is projected to reach $41.4 billion in 2012 and $79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacology.
The global revenue for single use technology reached $1.4 billion and $1.7 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.7% to nearly $3.0 billion for the period 2014-2019.
The fast-growing division of the pharmaceutical market includes generics and biologics. Biologics now account for over a third of all new drugs in clinical trials or awaiting FDA approval.15 U.S generic drug sales reached an estimated $70 billion, representing a quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favoring generics. Although generics make up only 22 percent of total prescription sales, its share of filled prescriptions has risen from 19 percent in 1984 to 88 percent in 2015. The research-based pharmaceutical industry is estimated to have spent nearly USD 149.8 billion globally on pharmaceutical R&D in 2015-16. Among all the industrial sectors, the research-based pharmaceutical industry has consistently invested the most in research and development, even in times of economic turmoil and monetary crisis.
According to the Quintiles IMS Institute predicts that the pharmaceutical market by 2021 will reach nearly USD 1,485 billion, by an increase of USD 350-380 billion from the USD 1,105 billion recorded in 2016. Global brand spending is forecast to increase to USD 815-832 billion in 2021. Global generic spending is expected to increase to USD 495-505 billion by 2021.
The United States share of global spending will increase from USD 461.7 billion in 2016 to USD 645-675 billion in 2021, while the European share of spending will grow from USD 151.8 billion to USD 170-200 billion. Meanwhile, pharmerging countries will spend nearly 315-345 USD billion in 2021 from 242.9 in 2016.
European pharmaceutical market is set to develop from 169 billion euros in 2015 to 206 billion euros ($229.5 billion) in 2022, showing a compound yearly development rate of 3.25 over the period.
As per another report from life science showcase insight organization Evaluate, development is to a great extent because of developments in oncology, in spite of the fact that progression change propels are additionally rising crosswise over other treatment zones including different sclerosis, constant heart disappointment, rheumatoid joint pain and Alzheimer's. The report is the first to investigate the European medication market to 2022, in view of agreement sedate estimates, using information from Evaluate's recently propelled "European Drug Forecasts" module.
"New advancements, prompting fundamentally enhanced patient results, accompany higher medication costs, doctor's eagerness to endorse, and, in this way, higher agreement tranquilize gauges," said Antonio Iervolino, Evaluate's head of determining.
"In a framework, eventually paid for by governments, this brings up issues on the manageability of the present financing model and introduces challenges for payers inEurope. To lessen the grating amongst payers and industry, another collective way to deal with financing should be set up, at last mirroring the advantages that a portion of the new developments are creating all through the entire medicinal services esteem chain."
Glance at Market of Pharma:
These data describe the outcome of the patient as defined in U.S reporting regulations. Serious means that one or more of the following outcomes were documented in the report: death, hospitalization, life threatening. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacy.
Harvard University | University of Cambridge | University of California, San Francisco | University College London | University of North Carolina | Karolinska Institute | Yale University | King's College London | University of California, San Diego | Cardiff University | Stanford University | The Imperial College of Science, Technology and Medicine | The University of Manchester | The University of Texas | Utrecht University | The University of Dundee | Columbia University | Monash University | University of Oxford | Pierre and Marie Curie University | Medical University of Vienna | Rockefeller University | Uppsala University | University of Pennsylvania | University of Zurich | University of Tuebingen | The Ohio State University | Radboud University Nijmegen| Norwegian University of Science and Technology | Vanderbilt University | McGill University | University of Hamburg | University of Lausanne | University of Paris Descartes | The University of Tokyo | University of California, Berkeley | Swiss Federal Institute of Technology Zurich | Kyoto University | University of Wisconsin – Madison | University of Arizona | University of South Florida | University of Utah | China Pharmaceutical University
University of Southern California | CUNY York College | Purdue University | University of Wisconsin-Madison | Albany College of Pharmacy and Health Sciences | University of North Carolina | University of Colorado | Oregon State University | Nova Southeastern University | Massachusetts College of Pharmacy and Health Sciences | University of Florida College of Pharmacy | University of Michigan College of Pharmacy | Campbell University School of Pharmacy | University of Pittsburgh School of Pharmacy | University of Georgia College of Pharmacy | Temple University School of Pharmacy | Ernest Mario School of Pharmacy | Skaggs School of Pharmacy | Eugene Applebaum College of Pharmacy and Health Sciences | University of North Carolina | University of Minnesota | University of California—San Francisco | University of Michigan—Ann Arbor | University of Texas—Austin | Ohio State University | University of Illinois—Chicago | University of Kentucky | Purdue University | University of Florida | University of Maryland—Baltimore | University of Pittsburgh | University of Southern California | University of Washington| University of Wisconsin—Madison | University of Arizona | University of Iowa | University of Tennessee Health Science Center | University of Utah | University of Kansas | Virginia Commonwealth University | University at Buffalo | University of Colorado—Denver | Auburn University | University of California—San Diego | University of Oklahoma | Northeastern University
Kingston University | Anglia Ruskin University | Aston University School of Life and Health Sciences | University of Birmingham | University of Brighton | Cardiff University | University of Huddersfield Chemical Sciences | University of Huddersfield Pharmacy | Liverpool John Moores University School of Pharmacy and Biomolecular Sciences | London Metropolitan University | Loughborough University | Newcastle University Northern Institute for Cancer Research | Nottingham Trent University School of Science and Technology | University of Nottingham School of Pharmacy | University of Strathclyde | University of Copenhagen | University of South Wales | University of Bradford | European University Cyprus | University of Groningen | University of Central Lancashire | University of Debrecen | Tu Braunschweig University | Marburg University | Greifswald University | Frankfurt University | Freiburg University | Kiel University | Wurzburg University | Fu Berlin University | Lomonosov Moscow State University | Saint-Petersburg State University | Novosibirsk State University
University of Tokyo | National University of Singapore | Kyoto University | University of Hong Kong | Peking University | Seoul National University | National Taiwan University | Osaka University | Tsinghua University | Chinese University of Hong Kong | Fudan University |The Hong Kong University of Science and Technology | Taipei Medical University | Mahidol University | Korea Advanced Institute of Science and Technology | Yonsei University | Shanghai Jiao Tong University | Nanyang Technological University | Chulalongkorn University | Tohoku University | Tokyo Medical and Dental University | Kyushu University |Nagoya University | Hokkaido University | Sungkyunkwan University | University of Science and Technology of China | Pohang University of Science and Technology | Korea University | University Malaya | Indian Institute of Science
Batna 2 University | University of Kinshasa | University of Lubumbashi | Ahram Canadian University | Alexandria University | British University in Egypt | Cairo University | German University in Cairo | Helwan University | Kafrelsheikh University | Mansoura University | Nahda University | Pharos University in Alexandria | Suez Canal University | Tanta University | Zagazig University | Addis Ababa University | Wollega University | Kwame Nkrumah University of Science and Technology | Kenya Methodist University | Kenyatta University | Elmergib University | University of Benghazi | University of Zawia | University of Misurata | University of Rwanda | Nelson Mandela Metropolitan University | North-West University | Rhodes University | University of KwaZulu | University of Limpopo | University of Pretoria | University of the Western Cape | University of the Witwaters | Ahfad University for Women | University of Khartoum | Omdurman Islamic University | Catholic University of Health and Allied Sciences | Kampala International University | Muhimbili University of Health and Allied Sciences | St. John's University of Tanzania | University of Monastir | Makerere University | Mbarara University of Science and Technology| University of Zambia | Harare Institute of Technology | University of Zimbabwe
3rd International Conference on Nano-medicine & Drug Delivery April 11-12, 2019 Paris, France; 14th Conference on Chemistry Research December 06-07, 2018 Amsterdam Netherlands; 2nd Edition of EuroSciCon Conference on Chemistry February 19-20, 2019 Prague, Czech Republic; 10th Edition of International Conference on Analytical Chemistry February 28-March 01, 2019 London, UK; European Congress on Pharmaceutics & Pharmaceutical Technology February 19-20, 2019 Prague, Czech Republic; International Conference on Clinical and Medical Case Reports November 19-20, 2018 Paris, France; 8th Edition EuroSciCon Conference on Clinical Pharmacy April 18-19, 2019 Paris, France; 22nd Edition of International Conference on Nano Engineering & Technology December 10-11, 2018 Rome, Italy; EuroSciCon Conference on Advanced Nanotechnology April 18-19, 2019 Paris, France; 8th Edition of International Conference on Internal Medicine & Patient Care March 25-26, 2019 Rome, Italy; 13th Edition of International Conference on Nanopharmaceutics and Advanced Drug Delivery August 29-31, 2019 London, UK; European Congress on Pharma May 30-31, 2019 Oslo, Norway; 18th World Pharma Congress March 18-20, 2019 Warsaw, Poland; 3rd International Conference On Pharmaceutical Chemistry December 07-08, 2018 Brussels, Belgium; 28th International Conference And Expo On Nanosciences And Nanotechnology Nov 26-28,2018 Barcelona, Spain; 18th Annual Pharmaceutical And Chemical Analysis Congress November 05-06, 2018 Madrid, Spain; 14th International Conference On Generic Drugs And Biosimilars November 15-16, 2018 Berlin, Germany; 23rd International Conference On Pharmaceutical Biotechnology December 10-11, 2018 Rome, Italy; World Congress and Exhibition on Pharmaceutics and Drug Delivery December 05-06, 2018 Madrid, Spain
3rd Edition of World Chemistry Conference February 25-26, 2019 Philadelphia, USA; 28th International Conference On Chemistry & Drug Designing 2018 Dec 05-06, 2018 Vancouver, Canada; 21st International Conference On Pharmaceutical & Bio-Inorganic Chemistry Oct 31- Nov 1, 2018 San Francisco, USA; 21st Global Conference On Pharmacogenomics, Biomarkers & Forensic Chemistry Oct 31- Nov 01, 2018 San Francisco, USA; 5th International Conference On Pain Medicine And Pain Management October 17-18, 2018, New York, USA; 13th International Conference On Biopharma And Biotherapeutics October 24-25, 2018 Boston, USA; 13th International Conference On Biologics And Biosimilars October 24-25, 2018 Boston, USA; 3rd International Conference On Internal Medicine & Hospital Medicine October 15-16, 2018 Ottawa, Canada; 2nd World Congress on Pharmacology and Toxicological Studies Edinburgh, Scotland November 8-10, 2018; International Conference on Pharmaceutical Nanotechnology and Nano Drug Delivery System Chicago, USA November 8-10, 2018; International Conference on Chemistry in Drug Discovery & Designing December 1-2, 2018 Chicago, Illinois, USA; 2nd International Conference and Exhibition on Pharmaceutics & Advanced Drug Delivery Systems December 7-8, 2018 Chicago, USA; 2nd International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems February 18-20, 2019 Paris, France; 9th World Congress on Clinical Pharmacy and Pharmacy Practice March 25-26, 2019 Amsterdam, Netherlands; 3rd International Conference on Nanostructures, Nanomaterials and Nanoengineering December 03-04, 2018 Toronto, Canada; 3rd World Drug Delivery and Formulations Summit April 15-16, 2019 Las Vegas, USA
Global Pharmaceutical and Pharma Industry Conference February 28-March 01, 2019 Osaka, Japan; Annual Conference On Nanoscience, Nanotechnology & Advanced Materials November 26-28, 2018 Bali, Indonesia; International Conference On Pharmacology And Toxicology October 18-19, 2018Dubai, UAE; 18th International Conference On Medicinal And Pharmaceutical Chemistry October 18-19, 2018 Dubai, UAE; 18th Annual Pharma Middle East Congress November 05-07, 2018 Abu Dhabi, UAE; 6th International Conference And Exhibition On Pharmacognosy, Phytochemistry & Natural Products December 03-04, 2018 Bangkok, Thailand; 20th World Conference On Pharmaceutical Chemistry And Drug Design December 10-11, 2018 Dubai, UAE; 10th Annual Congress On Drug Formulation & Analytical Techniques December 10-11, 2018 Dubai, UAE; 5th World Congress On Natural Products, Medicinal Plants And Traditional Medicines November 5-6, 2018 Singapore City, Singapore; World Congress On Bioorganic And Medicinal Chemistry November 12-13, 2018 Dubai, UAE; International conference on Pharmaceutics and Novel Drug Delivery Systems October 25-26, 2018 Tokyo, Japan; Global Pharma Summit November 23-24, 2018 Bangkok, Thailand; International Conference on Natural Products, Medicinal Plants & Marine Drugs November 26-28, 2018 Dubai, UAE; 2nd International Conference on Pharmaceutical Chemistry and Drug Discovery June 10-11, 2019 Bangkok, Thailand; Annual Meeting on Pharmacology and Therapeutics November 19-20, 2018 Abu Dhabi, UAE; 24th International Conference on Cancer Research and Pharmacology March 11-12, 2019 Singapore
Mylan | Astellas Pharma | Novo Nordisk | Boehringer Ingelheim | Allergan | Takeda | Bristol-Myers Squibb | Eli Lilly | Teva Pharmaceutical Industries | Amgen | AbbVie | AstraZeneca | GlaxoSmithKline | Gilead Sciences | Merck | Sanofi | Roche | Pfizer | Novartis | Bayer | Johnson and Johnson | QPS | Biocrates | ThioMatrix | Polymun Scientific | Croma-Pharma | Affiris | Aposcience | EverCyte | Octapharma | Teleflex Medical | Janssen Pharmaceuticals | Lonza | Bone Therapeutics | Formac Pharmaceuticals | Oncurious | Sanofi Genzyme | Alexion | Baxter | Chemnovatic | CSL Behring | Custom Pharmaceuticals | Fujirebio Europe | Galen Limited | Martindale Pharma | Novo Nordisk A/S | Petrone Group | Purna Pharmaceuticals | Shire | UCB Pharma | Uni-Pharma | Covidien | Fresenius Se | Fresenius Medical | Rhoen Klinikum | Morphosys | Stada Arzneim | Carl Zeiss Meditec | Freudenberg medical | Emergent biosolutions | Aran biomedical | Norgine | Lexogen | Haplogen | Octimet Oncology | Anacura | Ablynx | Novasep | Flen Pharma | Toxikon | Zoetis | Pharmavize | Galapagos | Eurogentec | LinaTech | Stada | Synthon | Ferring Pharmaceuticals | Lonza | UBC | Leo Pharma | Saniona | DanDrit Biotechnology | Taconic Biosciences | West Pharma
Gilead Sciences | Johnson & Johnson | Pfizer | Abbott Laboratories | Bristol Myers Squibb | Amgen | Biogen | Celgine Corporation | Merck & Co | Eli Lilly | Acura Pharmaceuticals | Alexion Pharmaceuticals | AMRI Global | Apricus Biosciences | BioCryst Pharmaceuticals | Biovista | Ceragenix Pharmaceuticals | Coherus BioSciences | Dynax pharmaceuticals | Endo International plc| Ensemble Therapeutics | Fabre-Kramer Pharmaceuticals | Genentech | H. K. Mulford Company | Impax Laboratories | Insys Therapeutics | Jones Pharma | KaloBios Pharmaceuticals | Lexicon Pharmaceuticals | Marathon Pharmaceuticals | Meyer Brothers Drug Company | NovaBay Pharmaceuticals | Nephroceuticals | Ovation Pharmaceuticals | Peregrine Pharmaceuticals | Pharmaceutical Research and Manufacturers of America | Proteon Therapeutics | Quark Pharmaceuticals| Reliant Pharmaceuticals | Sagent Pharmaceuticals | Sucampo Pharmaceuticals | Tonix Pharmaceuticals | Verus Pharmaceuticals
3-D Matrix | Agilent | BeiGene | BioDuro | China Biological Products | Fosun Pharma | Lumenis| MicroPort | Senju Pharmaceutical | Sihuan Pharmaceutical | Sinovac Biotech | DesigneRx Pharmaceuticals | Pharmadax | Denovo Biopharma | BioMarin Pharmaceuticals | Invitrogen | WuXi Apptec | AngioDynamics | SciGenom | Dishman Specialty Chemicals | Intas Pharmaceuticals | Zydus Cadila | Advinus Therapeutics | Sigma-Aldrich | Par Pharmaceutical | Gland Pharma | Natco Pharma | Haffkine Biopharmaceuticals | Allergan | Taisho Pharmaceutical | Dainippon Sumitomo | Wakunaga Pharmaceutical | Dainippon Sumitomo | Santen | Chugai Pharma| Kissei Pharmaceutical | WaVe Life Sciences | Mitsubishi Tanabe Pharma | Astellas | Daiichi Sankyo | AnGes | Kubota Pharmaceutical | Ohara Pharmaceutical | Daewon Pharma | Charles River Laboratories | Oxonc Development | Yungjin Pharmaceutical | Neopeutics | Austrianova Biotechnology | 3M | Clinuvel Pharmaceuticals | Micropoint Technologies | Sphaera Pharma | VolitionRx | China Chemical and Pharmaceutical Company| Foresee Pharmaceuticals
Fresenius Kabi Distribution | Luced Agencies | Akacia Health | Roche Pharmaceuticals | Biotech Laboratories | Allied Drug Company | Janssen-cilag | Teva Pharmaceuticals | Medimoc Sarl | Bayer International Service | Boehringer Ingelheim | Columbia Pharmaceuticals | Ultimate Sport Nutrition | Astra Zeneca Pharmaceuticals | Resmed Pharmaceuticals | Servier Laboratories | Embassy Pharmaceuticals | Amalgamated Pharmaceuticals | New S Buys | Afrox Limited | Amka Pharmaceuticals | Astra Pharmaceuticals | Brunel Laboratoria | Dia-Kure Ltd | Eden Pharmaceuticals Prod | Geo Schwulst Laboratories | GM Pharmaceuticals | Hersol Manufacturing Laboratories | Intramed | Johnson & Johnson | Kyron Laboratories | Merck Generics RSA | Novo Nordisk | Pharma Natura | Pharmacare Ltd | Resmed Pharmaceuticals | S N Pharmaceuticals | Smith & Nephew Pharmaceuticals | Smithkline Beecham
Journal of Pharmaceutical Sciences | International Journal of Pharmaceutics | The Pharmaceutical Journal of Pharmaceutical Research | European Journal of Pharmaceutics and Biopharmaceutics | Molecular Pharmaceutics | European Journal of Pharmaceutical Sciences | Asian Journal of Pharmaceutics | Journal of Pharmacy and Pharmacology | Indian Journal of Pharmaceutical Sciences | Journal of Pharmacy and Pharmaceutical Sciences | Drug Development and Industrial Pharmacy | Journal of Pharmacy Practice | American Journal of Pharmaceutical Education | International Journal of Drug Development & Research | Journal of Bioequivalence & Bioavailability | Journal of Bioanalysis & Biomedicine | Journal of Pharmacogenomics & Pharmacoproteomics | Journal of Vaccines & Vaccination | Journal of Drug Metabolism & Toxicology | Drug Designing: Open Access | Medicinal & Aromatic Plants | Journal of Biomolecular Research & Therapeutics | Research & Reviews in Pharmacy and Pharmaceutical Sciences | Journal of Molecular Pharmaceutics & Organic Process Research | Journal of Developing Drugs | Journal of Pharmaceutics & Drug Delivery Research | Molecular Enzymology and Drug Targets | Research & Reviews: Journal of Pharmaceutics and Nanotechnology | Journal of Pharmacokinetics & Experimental Therapeutics
Royal Pharmaceutical Society | International Pharmaceutical Federation | International Pharmaceutical Students' Federation | European Association of Employed Community Pharmacists in Europe | European Pharmaceutical Union | Pharmaceutical Group of the European Union | Pharmaceutical Society of Australia | The Pharmacy Guild of Australia | The Society of Hospital Pharmacists of Australia | Canadian Pharmacists Association | Chinese Pharmaceutical Association | Danish Association of Pharmaconomists | Indian Pharmacist Association | Pharmaceutical Society of Ireland | Kuwait Pharmaceutical Association | Pharmaceutical Society Of New Zealand | Norwegian Pharmacy Association | National Pharmacy Association | American Association of Colleges of Pharmacy | American Pharmacists Association | American Society for Pharmacy Law | American Society of Consultant Pharmacists | American Society of Health-System Pharmacists | Professional Compounding Centers of America | American College of Clinical Pharmacy | Canadian Society of Hospital Pharmacists | Pharmaceutical Association of Mauritius | Pakistan Pharmacists Association | Philippine Pharmacists Association | College of Psychiatric and Neurologic Pharmacists
Nasal sprays | Transdermal patches | Analytical nebulizer | Infusion pump | Jet injector | Bifurcated needle | Cypher stent | Dry-powder inhaler | Drug-eluting stent | Elixir | Epinephrine autoinjector | HumaPen | Mouthwash | Nanoneedle | Ommaya reservoir | Phonophoresis | Pill splitting | Rebiject II | Relative analgesia machine | Vesosome | Zydis